Logo Image
|Articles|April 4, 2016

Therapeutic Innovation & Regulatory Science (TIRS): Focus on Pharmaceutical Compounding

Author(s)DIA

Pharmaceutical compounding is an essential aspect of medicine in the US, although with inherent risks that must be understood and managed. In May 2016, the Special Section of TIRS overviews the history of compounding, identifies the special challenges associated with the practice, and offers improvements for patient safety.

Read more here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more